Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, August 22, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.
Salix Pharmaceuticals, Ltd. Research Reports
On August 19, 2014, Salix Pharmaceuticals, Ltd. (Salix) announced that it has received a notice of the early termination of the waiting period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its previously announced combination transaction with Cosmo Pharmaceuticals S.p.A. The Company stated that the waiting period was scheduled to expire on August 21, 2014. According to Salix, the termination of the waiting period satisfies a condition to the closing of the transaction, while completion of the transaction is still subject to Salix shareholders' approval and other closing conditions. Following the news, the Company's stock surged 15.54% to $160.80. The full research reports on Salix are available to download free of charge at:
Allergan, Inc. Research Reports
On August 18, 2014, Allergan, Inc. (Allergan) announced the appointment of Jim Hindman as the Executive Vice President, Finance and Business Development, CFO of the Company with immediate effect. The Company informed that Jim Hindman has previously served Allergan as Senior Vice President, Treasury, Risk and Investor Relations since 2002. Jim Hindman succeeds Jeff Edwards who has decided step down from the post of CFO due to family commitments; however, Mr. Jeff Edwards will continue his association with the Company in a non-executive officer capacity to facilitate smooth transition. David E.I. Pyott, Allergan's Chairman of the Board and CEO, commented, "We are pleased to name Jim Hindman as Allergan's Chief Financial Officer. Jim has been an instrumental member of our organization for many years, and particularly during the past few months, has played an important leadership role." The full research reports on Allergan are available to download free of charge at:
Valeant Pharmaceuticals Intl Inc. Research Reports
On August 15, 2014, Valeant Pharmaceuticals Intl Inc. (Valeant) announced that it has extended the expiration date of its exchange offer to acquire all of the outstanding shares of Allergan, Inc. (Allergan) to December 31, 2014 from August 15, 2014. Valeant stated that all other terms and conditions of the exchange offer remain unchanged. According to the depository of the exchange offer, as of 9:00 a.m., New York City time on August 15, 2014, a total of c.12.5 million shares of Allergan common stock were validly tendered and not properly withdrawn in the exchange offer. The full research reports on Valeant are available to download free of charge at:
HCA Holdings Inc. Research Reports
On August 19, 2014, HCA Holdings Inc.'s (HCA Holdings) stock declined 0.26% to end the trading session at $68.69, underperforming the S&P 500 that gained 0.50% over the same trading session. Shares in HCA Holdings initiated the session at $69.15 and oscillated in the range of $67.88 - $69.19, thereby, creating a 52-week high of $69.19. Over the past one month, the stock has returned 10.01% outperforming the S&P 500 that returned 0.17% over the same period of time. On July 29, 2014, the Company reported Q2 2014 revenues of $9.2 billion, up 9.2% YoY, while net income attributable to HCA Holdings stood at $483 million, up 14.2% YoY. Since the release of the Q2 2014 earnings, the stock of the Company has surged 5.56%. The full research reports on HCA Holdings are available to download free of charge at:
Puma Biotechnology Inc. Research Reports
On August 11, 2014, Puma Biotechnology Inc. (Puma Biotechnology) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 loss from operations of $38.9 million, compared to loss from operations of $12.7 million in Q2 2013. The Company's Q2 2014 net loss stood at $38.8 million or $1.29 diluted loss per share, compared to net loss of $12.6 million or $0.44 diluted loss per share in Q2 2013. In H1 2014, Puma Biotechnology's loss from operations increased to $58.7 million from $24.5 million in H1 2013, while net loss stood at $58.6 million, compared to net loss of $24.4 million in H1 2013. The full research reports on Puma Biotechnology are available to download free of charge at
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.